Literature DB >> 25008324

A WXW motif is required for the anticancer activity of the TAT-RasGAP317-326 peptide.

David Barras1, Nadja Chevalier1, Vincent Zoete2, Rosemary Dempsey1, Karine Lapouge3, Monilola A Olayioye4, Olivier Michielin2, Christian Widmann5.   

Abstract

TAT-RasGAP317-326, a cell-permeable 10-amino acid-long peptide derived from the N2 fragment of p120 Ras GTPase-activating protein (RasGAP), sensitizes tumor cells to apoptosis induced by various anticancer therapies. This RasGAP-derived peptide, by targeting the deleted in liver cancer-1 (DLC1) tumor suppressor, also hampers cell migration and invasion by promoting cell adherence and by inhibiting cell movement. Here, we systematically investigated the role of each amino acid within the RasGAP317-326 sequence for the anticancer activities of TAT-RasGAP317-326. We report here that the first three amino acids of this sequence, tryptophan, methionine, and tryptophan (WMW), are necessary and sufficient to sensitize cancer cells to cisplatin-induced apoptosis and to reduce cell migration. The WMW motif was found to be critical for the binding of fragment N2 to DLC1. These results define the interaction mode between the active anticancer sequence of RasGAP and DLC1. This knowledge will facilitate the design of small molecules bearing the tumor-sensitizing and antimetastatic activities of TAT-RasGAP317-326.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Anticancer Peptide; Cell Migration; Cell-penetrating peptide (CPP); Deleted in Liver Cancer 1 (DLC1); Docking; GTPase-activating Protein (GAP); Peptides; RasGAP; Sensitizer; TAT-RasGAP317–326

Mesh:

Substances:

Year:  2014        PMID: 25008324      PMCID: PMC4156047          DOI: 10.1074/jbc.M114.576272

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

Review 1.  Combinatorial alanine-scanning.

Authors:  K L Morrison; G A Weiss
Journal:  Curr Opin Chem Biol       Date:  2001-06       Impact factor: 8.822

2.  Deleted in liver cancer 1 controls cell migration through a Dia1-dependent signaling pathway.

Authors:  Gerlinde Holeiter; Johanna Heering; Patrik Erlmann; Simone Schmid; Ruth Jähne; Monilola A Olayioye
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

Review 3.  Current trends in the clinical development of peptide therapeutics.

Authors:  Pauline M Saladin; Bodi D Zhang; Janice M Reichert
Journal:  IDrugs       Date:  2009-12

4.  Functional cross-talk between ras and rho pathways: a Ras-specific GTPase-activating protein (p120RasGAP) competitively inhibits the RhoGAP activity of deleted in liver cancer (DLC) tumor suppressor by masking the catalytic arginine finger.

Authors:  Mamta Jaiswal; Radovan Dvorsky; Ehsan Amin; Sarah L Risse; Eyad K Fansa; Si-Cai Zhang; Mohamed S Taha; Aziz R Gauhar; Saeideh Nakhaei-Rad; Claus Kordes; Katja T Koessmeier; Ion C Cirstea; Monilola A Olayioye; Dieter Häussinger; Mohammad R Ahmadian
Journal:  J Biol Chem       Date:  2014-01-17       Impact factor: 5.157

5.  Caspase-3 and RasGAP: a stress-sensing survival/demise switch.

Authors:  Hadi Khalil; Mathieu J M Bertrand; Peter Vandenabeele; Christian Widmann
Journal:  Trends Cell Biol       Date:  2013-09-02       Impact factor: 20.808

6.  The Ras-GTPase-activating protein SH3 domain is required for Cdc2 activation and mos induction by oncogenic Ras in Xenopus oocytes independently of mitogen-activated protein kinase activation.

Authors:  M Pomerance; M N Thang; B Tocque; M Pierre
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

7.  A RasGAP-derived cell permeable peptide potently enhances genotoxin-induced cytotoxicity in tumor cells.

Authors:  David Michod; Jiang-Yan Yang; Jianhua Chen; Christophe Bonny; Christian Widmann
Journal:  Oncogene       Date:  2004-11-25       Impact factor: 9.867

8.  Fragment N2, a caspase-3-generated RasGAP fragment, inhibits breast cancer metastatic progression.

Authors:  David Barras; Girieca Lorusso; Benoît Lhermitte; David Viertl; Curzio Rüegg; Christian Widmann
Journal:  Int J Cancer       Date:  2014-03-04       Impact factor: 7.396

9.  p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities.

Authors:  X-Y Yang; M Guan; D Vigil; C J Der; D R Lowy; N C Popescu
Journal:  Oncogene       Date:  2009-01-19       Impact factor: 9.867

Review 10.  DLC-1:a Rho GTPase-activating protein and tumour suppressor.

Authors:  Marian E Durkin; Bao-Zhu Yuan; Xiaoling Zhou; Drazen B Zimonjic; Douglas R Lowy; Snorri S Thorgeirsson; Nicholas C Popescu
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

View more
  7 in total

1.  TAT-RasGAP317-326 kills cells by targeting inner-leaflet-enriched phospholipids.

Authors:  Marc Serulla; Gabriel Ichim; Filip Stojceski; Gianvito Grasso; Sergii Afonin; Mathieu Heulot; Tim Schober; Robyn Roth; Cédric Godefroy; Pierre-Emmanuel Milhiet; Kushal Das; Ana J García-Sáez; Andrea Danani; Christian Widmann
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-30       Impact factor: 11.205

2.  The EnvZ/OmpR Two-Component System Regulates the Antimicrobial Activity of TAT-RasGAP317-326 and the Collateral Sensitivity to Other Antibacterial Agents.

Authors:  Christian Widmann; Nicolas Jacquier; Maria Georgieva; Tytti Heinonen; Simone Hargraves; Trestan Pillonel
Journal:  Microbiol Spectr       Date:  2022-05-17

3.  Assessment of the chemosensitizing activity of TAT-RasGAP317-326 in childhood cancers.

Authors:  Nadja Chevalier; Nicole Gross; Christian Widmann
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

4.  The Anticancer Peptide TAT-RasGAP317-326 Exerts Broad Antimicrobial Activity.

Authors:  Mathieu Heulot; Nicolas Jacquier; Sébastien Aeby; Didier Le Roy; Thierry Roger; Evgeniya Trofimenko; David Barras; Gilbert Greub; Christian Widmann
Journal:  Front Microbiol       Date:  2017-06-07       Impact factor: 5.640

Review 5.  Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review).

Authors:  Wararat Chiangjong; Somchai Chutipongtanate; Suradej Hongeng
Journal:  Int J Oncol       Date:  2020-07-10       Impact factor: 5.650

6.  DLC1 Is a Prognosis-Related Biomarker Correlated With Tumor Microenvironment Remodeling in Endometrial Carcinoma.

Authors:  Yalan Wu; Li-E Zheng; Shumin Chen; Chengyu Lv; Yuxiu Huang
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

7.  The TAT-RasGAP317-326 anti-cancer peptide can kill in a caspase-, apoptosis-, and necroptosis-independent manner.

Authors:  Mathieu Heulot; Nadja Chevalier; Julien Puyal; Christiane Margue; Sébastien Michel; Stephanie Kreis; Dagmar Kulms; David Barras; Aimable Nahimana; Christian Widmann
Journal:  Oncotarget       Date:  2016-09-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.